GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotech company specializing in developing drugs for serious diseases. It dominates the cystic fibrosis treatment market. Its stock price reflects this success and the expectation of breakthroughs in other areas, such as gene therapy.
Share prices of companies in the market segment - Specialized pharma
Vertex is a biotech company dominating the cystic fibrosis treatment segment and actively developing new areas. We classify it as a Specialized Pharma company, and the chart below reflects the dynamics of the entire industry, where a single successful drug can create a giant.
Broad Market Index - GURU.Markets
Vertex Pharmaceuticals is a biotech company leading the development of drugs to treat cystic fibrosis. Its focus on innovation makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Vertex is outperforming the overall market.
Change in the price of a company, segment, and market as a whole per day
VRTX - Daily change in the company's share price Vertex Pharmaceuticals
For Vertex, a leader in cystic fibrosis treatment, daily price changes are a measure of its response to research breakthroughs and financial results. The graph of these fluctuations is unspectacular, but it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized pharma
The biotech sector, where Vertex Pharmaceuticals is a leader in cystic fibrosis treatment, is extremely volatile. This chart shows the average daily performance of the entire industry. A comparison with VRTX shares helps us understand whether its dominant position in one niche makes it more or less stable than its diversified competitors.
Daily change in the price of a broad market stock, index - GURU.Markets
Vertex Pharmaceuticals is a leader in developing drugs to treat cystic fibrosis. The biotech sector is known for its high volatility. The chart below shows average daily fluctuations in this industry, allowing one to assess how Vertex's performance aligns with overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Vertex Pharmaceuticals
Vertex is a biotech leader with a dominant position in cystic fibrosis treatment. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform, which is focused on new breakthrough treatments, as the chart illustrates.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Vertex Pharmaceuticals stands out in the sector thanks to its dominance in cystic fibrosis treatment. While many pharmaceutical companies rely on a broad portfolio, Vertex focuses on breakthrough technologies in specific niches. This allows it to demonstrate growth that often outpaces the industry average, as reflected in the chart below.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vertex Pharmaceuticals specializes in developing drugs for rare diseases, particularly cystic fibrosis. Its near-monopoly position in this niche ensures stable growth independent of economic conditions. Vertex's stock performance exemplifies how a scientific breakthrough in one area can create a company that consistently outperforms the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Vertex Pharmaceuticals
The performance of Vertex Pharmaceuticals, a biotech focused on treating cystic fibrosis, reflects its dominant position in this niche. Monthly price fluctuations depend on sales data for its drugs and, more importantly for the future, news about clinical trials in new therapeutic areas.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
This chart reflects the dynamics of the biotech sector, where Vertex holds a unique position as a leader in cystic fibrosis treatment. Its steady growth in a volatile sector demonstrates the strength of its franchise and the anticipation of its new developments in other areas.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vertex Pharmaceuticals is a biotech company leading the treatment of cystic fibrosis. Their business is built on a unique scientific platform and a strong market position. The chart below shows overall market sentiment, but Vertex shares often follow their own trajectory, driven by clinical trial results and the commercial success of their drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotech company dominating the cystic fibrosis treatment market. Its weekly stock price is driven by news about the expansion of its drug portfolio and, more importantly, by clinical trial results in new therapeutic areas, such as gene therapy and pain management.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Vertex, with its monopoly on cystic fibrosis treatments, often follows its own trajectory, independent of the biotech sector. News about its research in other areas, such as gene therapy, is a unique driver. The chart shows how its dominant position and scientific breakthroughs differentiate it from the industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Vertex Pharmaceuticals is a leader in cystic fibrosis treatment. Its dominant position in this niche ensures the company's stable growth, often independent of market conditions. The chart shows how its scientific advances are enabling its stock to maintain its own upward trajectory.
Market capitalization of the company, segment and market as a whole
VRTX - Market capitalization of the company Vertex Pharmaceuticals
Vertex Pharmaceuticals' market capitalization shows how the market rewards the biotech for its dominance in treating a rare disease. Its impressive growth in the chart is based on its monopoly in cystic fibrosis therapy. The company's valuation reflects investors' belief that its scientific platform will enable it to succeed in other areas.
VRTX - Share of the company's market capitalization Vertex Pharmaceuticals within the market segment - Specialized pharma
Vertex Pharmaceuticals is a leader in cystic fibrosis treatment, holding a near-monopoly on the market. Its high market capitalization reflects the success of its drugs, which have dramatically altered the course of the disease, and its potential to develop treatments for other genetic diseases.
Market capitalization of the market segment - Specialized pharma
Here's a chart showing the biotech sector's market capitalization, and Vertex Pharmaceuticals is its leader in a highly specific and profitable niche: cystic fibrosis treatment. The dynamics of this market demonstrate how focusing on rare diseases can lead to the creation of a monopoly company with enormous profit margins.
Market capitalization of all companies included in a broad market index - GURU.Markets
Vertex Pharmaceuticals is a biotech company that dominates the cystic fibrosis treatment market. Its high market capitalization is based on its monopoly in this niche and promising developments. The chart below shows how leadership in rare disease treatments generates enormous value.
Book value capitalization of the company, segment and market as a whole
VRTX - Book value capitalization of the company Vertex Pharmaceuticals
Vertex Pharmaceuticals's tangible foundation is its R&D centers and manufacturing facilities, focused on treating rare diseases, particularly cystic fibrosis. Its book value reflects the research-intensive nature of its business. The chart tells the story of how dominance in one therapeutic niche allows the company to accumulate capital for breakthroughs in other areas.
VRTX - Share of the company's book capitalization Vertex Pharmaceuticals within the market segment - Specialized pharma
Intercontinental Exchange (ICE) owns the New York Stock Exchange (NYSE) and other exchanges. The chart shows its share of the exchange industry's physical assets. This includes not only the iconic building on Wall Street but also a global network of data centers where trillions of dollars of trading take place.
Market segment balance sheet capitalization - Specialized pharma
Vertex Pharmaceuticals is a biotech company focused on innovation. Pharmaceuticals, as the chart shows, are capital-intensive. Vertex invests in R&D, but producing its cystic fibrosis drugs also requires significant and complex manufacturing assets.
Book value of all companies included in the broad market index - GURU.Markets
Vertex Pharmaceuticals is a biotech company that has revolutionized the treatment of cystic fibrosis. Its high book value reflects not so much its manufacturing plants as its monopoly in the field and the enormous value of its patents, which generate billions of dollars in revenue.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Vertex Pharmaceuticals
Vertex Pharmaceuticals is a company with a unique monopoly in the treatment of cystic fibrosis. The enormous premium it commands is a reflection of this monopoly, its high profitability, and its potential to expand its technologies to other diseases.
Market to book capitalization ratio in a market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company with an absolute monopoly in the treatment of cystic fibrosis. Its valuation is based on this dominant franchise and developments in other areas. This chart shows the enormous premium the market pays for its scientific leadership and the virtually guaranteed cash flow from its unique drugs.
Market to book capitalization ratio for the market as a whole
Vertex Pharmaceuticals is a biotech company leading the treatment of cystic fibrosis. Its value is based on its dominant franchise and scientific developments. Given the overall market trends visible in the chart, Vertex's high premium reflects its monopoly position in its niche and the potential to develop new breakthrough drugs.
Debts of the company, segment and market as a whole
VRTX - Company debts Vertex Pharmaceuticals
For Vertex Pharmaceuticals, a leader in cystic fibrosis treatment, its virtually complete absence of debt is a sign of its unique position. Its market monopoly and ultra-high profitability allow the company to fund all of its ambitious R&D projects solely from cash flow. This chart demonstrates its exceptional financial independence.
Market segment debts - Specialized pharma
Vertex Pharmaceuticals is a biotech company that dominates the cystic fibrosis drug market. This monopoly provides it with enormous and growing cash flows, allowing Vertex to fund research in other areas with virtually no debt. This chart exemplifies the exceptional financial position of a company with a successful blockbuster drug.
Market debt in general
Vertex Pharmaceuticals is a biotech company that is the undisputed leader in the treatment of cystic fibrosis. This success has generated enormous cash flows, which it is investing in drug development in other areas. This total debt chart allows us to assess Vertex's financial independence thanks to its dominant franchise.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotech company dominating the cystic fibrosis treatment market. This chart shows the financial position of the company, which has a highly profitable franchise. Its low debt reflects its ability to use its massive revenues to fund R&D in new therapeutic areas and diversify its business.
Market segment debt to market segment book capitalization - Specialized pharma
Vertex Pharmaceuticals is a biotech company specializing in developing drugs for serious diseases, particularly cystic fibrosis. Its success is based on scientific breakthroughs. This chart shows how the company finances its expensive research. It compares its debt to the sector's market capitalization, reflecting its financial model.
Debt to book value of all companies in the market
Vertex Pharmaceuticals, a leader in cystic fibrosis treatment, has a highly profitable business, allowing it to fund R&D internally. This chart clearly demonstrates this. It compares its extremely low debt load with the market average, highlighting its unique position and financial independence.
P/E of the company, segment and market as a whole
P/E - Vertex Pharmaceuticals
This chart reflects the high valuation of Vertex Pharmaceuticals, a biotech company that has built a near-monopoly on cystic fibrosis treatments. Its very high P/E reflects this unique position and investors' hope that the company can replicate its success in treating other rare diseases.
P/E of the market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company that is a leader and a near-monopoly in the treatment of cystic fibrosis. The company is actively investing in drug development in other areas. This chart shows the average valuation for the biotech sector, clearly demonstrating the significant premium investors are paying for Vertex's dominant position in its niche.
P/E of the market as a whole
Vertex Pharmaceuticals is a biotech company that has revolutionized the treatment of cystic fibrosis by developing drugs that target the underlying cause of the disease. Its valuation is based on its monopoly position in this field and the potential for development in other areas, such as gene therapy. Its business is largely independent of economic cycles, as reflected in this chart.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotech company that is a leader in the treatment of cystic fibrosis. This chart reflects investor expectations regarding its near-monopoly position in this field and its potential to develop drugs for other diseases. The valuation is based on forecasts for the expansion of existing drugs and the success of new research.
%20P%2FE%20Vertex%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Vertex-Pharmaceuticals&v=1772613408565 "Chart of the company's future (projected) P/E Vertex Pharmaceuticals")
Future (projected) P/E of the market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company that is a leader in the treatment of cystic fibrosis and is actively developing drugs for other serious diseases. This chart reflects the market's faith in its scientific innovation. Comparing its earnings forecasts with the sector reveals the premium investors are paying for its dominant position and future developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772613408614 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Vertex Pharmaceuticals is a biotech company that is a leader in cystic fibrosis treatment and is actively pursuing new therapeutic areas. Its story exemplifies how scientific innovation can create an entire market niche. Amid the general market fluctuations shown by this chart, Vertex demonstrates growth based on fundamental science.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772613408654 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a biotech company specializing in developing drugs for serious diseases, particularly cystic fibrosis. Its profits depend almost entirely on monopoly positions in this therapeutic area. This chart illustrates how a scientific breakthrough and a focus on a single niche can create an extremely profitable business.
Profit of companies in the market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company that dominates the cystic fibrosis treatment market. Its innovative drugs have dramatically changed the lives of patients with this rare disease. Vertex's story is a shining example of how focusing on one complex disease can lead to the creation of a highly profitable franchise and set the standard for the entire industry.
Overall market profit
Vertex Pharmaceuticals is a biotech company that has transformed the treatment of cystic fibrosis, transforming it from a fatal condition into a manageable, chronic one. The company is a leader in this field and is actively researching other rare genetic diseases. Vertex's success demonstrates how focused scientific research can lead to the creation of breakthrough medications.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Vertex Pharmaceuticals
Vertex Pharmaceuticals specializes in developing drugs for cystic fibrosis, where it is the undisputed leader. This chart shows expectations for its dominance in this market, as well as the company's success in developing drugs for other rare diseases using innovative technologies.
%20profit%20of%20the%20company%20Vertex%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Vertex-Pharmaceuticals&v=1772613408733 "Graph of future (projected) profit of the company Vertex Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company that is a leader in cystic fibrosis treatment and is actively developing drugs in other areas. This graph shows the projected revenue trajectory for the biopharmaceutical industry. This data allows us to assess how Vertex's unique scientific platform is enabling market-beating growth.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772613408744 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
The trajectory on this chart reflects expectations for a biotech company focused on treating rare diseases. Vertex Pharmaceuticals' profit outlook depends almost entirely on sales of its cystic fibrosis drugs. Success in clinical trials in other areas, such as gene therapy, is key to future diversification.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772613408772 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Vertex Pharmaceuticals
Vertex Pharmaceuticals specializes in developing drugs for serious diseases, leading the way in cystic fibrosis treatment. This chart shows how highly the market values its dominant position in this niche. The high multiple reflects expectations for its current pipeline and confidence in its scientific platform for developing new drugs.
P/S market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company that is the undisputed leader in the treatment of cystic fibrosis. The company is actively investing in the development of drugs for other serious diseases. This chart shows the average revenue estimate in the biotech sector. It helps understand the market premium for Vertex's monopoly position in its niche.
P/S of the market as a whole
Vertex Pharmaceuticals is a biotech company specializing in developing drugs for serious diseases, particularly cystic fibrosis, where it is the clear leader. This graph, showing Vertex's average revenue estimate, helps understand how the market views its scientific platform and its ability to expand its dominance into new areas.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotech company that is a leader in the treatment of cystic fibrosis. Its future depends on maintaining its dominance in this field and successfully developing drugs for other diseases, such as sickle cell anemia. This chart shows how investors view its scientific pipeline and potential for entering new markets.
%20P%2FS%20Vertex%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Vertex-Pharmaceuticals&v=1772613408988 "The graph of the company's future (projected) P/S Vertex Pharmaceuticals")
Future (projected) P/S of the market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company that dominates the cystic fibrosis treatment market and is actively developing drugs in other areas, including gene therapy. This chart shows how investors view its scientific leadership. Are they willing to pay a premium for its innovation and potential to develop treatments for rare and complex diseases?
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772613409014 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Vertex Pharmaceuticals is a biotech company with a monopoly on cystic fibrosis treatment. Its revenue is highly predictable thanks to its unique drugs. The company's success in developing drugs for other rare diseases exemplifies the innovation in pharmaceuticals that underpins the long-term optimism in the sector, as reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772613409040 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotech company that is a leader in the treatment of cystic fibrosis. Its revenue is generated almost entirely by sales of innovative drugs for this rare disease. This chart illustrates how a scientific breakthrough can create and dominate an entire market niche.
Sales of companies in the market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company that has transformed the treatment of cystic fibrosis by creating drugs that target the underlying cause of the disease. Its strategy is focused on breakthrough innovation. This chart shows overall sales in the pharmaceutical sector, allowing one to assess how one company's scientific discoveries can create and conquer an entirely new multi-billion dollar market.
Overall market sales
Vertex Pharmaceuticals is a biotechnology company leading the development of drugs for the treatment of cystic fibrosis. Its business model is based on the creation of breakthrough drugs for rare diseases. This overall economic activity graph for Vertex is indirectly important because it impacts the ability of healthcare systems worldwide to finance costly treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotech company leading the treatment of cystic fibrosis. The company's future revenue depends on sales of its drugs in this area and the success of its research in other therapeutic areas, such as gene therapy. This chart shows how analysts assess the potential of the current franchise and its research pipeline.
%20sales%20of%20the%20company%20Vertex%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Vertex-Pharmaceuticals&v=1772613409205 "Schedule of future (projected) sales of the company Vertex Pharmaceuticals")
Future (projected) sales of companies in the market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company specializing in developing drugs to treat cystic fibrosis and other serious diseases. This chart displays projected revenue for the entire pharmaceutical sector. While it provides an overview of overall trends, Vertex is more focused on assessing the potential of its unique rare disease franchise.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772613409228 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Vertex Pharmaceuticals is a biotechnology company specializing in the development of drugs for cystic fibrosis and other serious diseases. Its business model is based on innovation and the treatment of rare diseases. This graph, reflecting the overall state of the economy, is less important for Vertex in the short term, but it impacts the long-term ability of healthcare systems around the world to finance very expensive cutting-edge therapies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772613409291 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotech company that is a leader in the treatment of cystic fibrosis. This chart illustrates how profitable a monopoly can be in treating a rare disease. The company's high efficacy is based on its unique drugs, and its key goal is to expand its portfolio into other therapeutic areas.
Market segment marginality - Specialized pharma
Vertex Pharmaceuticals is a biotech company that is the undisputed leader in the treatment of cystic fibrosis. Its drugs are unique and vital for patients, giving the company enormous pricing power. This metric illustrates how its monopoly position in its therapeutic niche allows Vertex to achieve one of the highest profit margins in the industry.
Market marginality as a whole
Vertex Pharmaceuticals is a biotech company that dominates the cystic fibrosis treatment market. This chart shows overall profitability. It illustrates how focusing on a single complex disease and developing revolutionary drugs can lead to a monopoly position and exceptionally high profitability, which funds research in other areas.
Employees in the company, segment and market as a whole
Number of employees in the company Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotech company that has transformed the treatment of cystic fibrosis by creating drugs that target the underlying cause of the disease. This graph shows a focused team of scientists. The growth is driven by expanded research into new therapeutic areas, such as gene therapy and type 1 diabetes.
Share of the company's employees Vertex Pharmaceuticals within the market segment - Specialized pharma
This chart shows Vertex Pharmaceuticals' leadership in cystic fibrosis treatment. Its share of employees in this narrow but important pharmaceutical segment reflects its scientific dominance. This team of scientists has developed breakthrough drugs that modify the course of this rare genetic disease, a shining example of success in precision medicine.
Number of employees in the market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company known for its breakthrough drugs for the treatment of cystic fibrosis. The company's focus on innovative science and complex diseases attracts top researchers. This chart demonstrates the research-intensive nature of the specialty pharmaceutical sector, where Vertex is a leader in R&D quality.
Number of employees in the market as a whole
Vertex Pharmaceuticals is a biotech company known for its absolute dominance (monopoly) in the treatment of cystic fibrosis (CF). They also develop drugs for other rare diseases and pain. This graph of total employment reflects the state of the insurance system. Their business model is based on the high cost of innovation, which only developed healthcare systems can cover.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals specializes in treating rare diseases, particularly cystic fibrosis. Its dominant position in this market and high drug prices translate into enormous revenue. Its astronomical per-employee ratio reflects the value of its patents and scientific breakthroughs.
%20of%20the%20company%20Vertex%20Pharmaceuticals%20(VRTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Vertex-Pharmaceuticals-VRTX&v=1772613409489 "Chart of market capitalization per employee (in thousands of dollars) of the company Vertex Pharmaceuticals (VRTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Vertex Pharmaceuticals (VRTX) has a near-monopoly on cystic fibrosis treatments. This franchise generates colossal cash flow with a relatively small, elite R&D and sales staff. This graph should show an extremely high return on investment per employee, reflecting the incredible profitability of its scientific niche.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772613409554 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Vertex Pharmaceuticals is a biotech company specializing in developing drugs for rare diseases, particularly cystic fibrosis. This chart demonstrates its extremely high cost per employee. This is a result of its dominance in its niche and the high price of its life-saving drugs, which generates enormous R&D costs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772613409570 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals (VRTX) is a biotech company with a de facto monopoly on the treatment of cystic fibrosis (CF). This chart exemplifies R&D dominance. By creating breakthrough CF drugs, the company has secured a market with a high barrier to entry. This provides the company with incredible profits per employee engaged in R&D and sales.
%20Chart%20Vertex%20Pharmaceuticals%20(VRTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Vertex-Pharmaceuticals-VRTX&v=1772613409599 "Company Profit Per Employee (in thousands of dollars) Chart Vertex Pharmaceuticals (VRTX)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Vertex Pharmaceuticals (VRTX) is a leader in cystic fibrosis treatment. This chart shows the benchmark for "specialized pharma." In this sector (orphan and rare diseases), employee profitability is exorbitant. Monopolistic companies in their niche set very high drug prices, which sets an astronomical benchmark.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772613409609 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Vertex Pharmaceuticals is a biotech company leading the treatment of cystic fibrosis. Its strategy is focused on rare diseases and the development of revolutionary drugs. This chart demonstrates the exceptional profitability of its business model, where scientific breakthroughs in a narrow niche and patent-protected drugs generate enormous profits per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772613409628 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals is a biotech company specializing in drugs for cystic fibrosis and other rare diseases. This chart demonstrates exceptional performance based on scientific breakthroughs. Dominance in its niche allows the company to charge high prices and generate enormous revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Vertex-Pharmaceuticals-VRTX&v=1772613409640 "Sales chart per company employee Vertex Pharmaceuticals (VRTX)")
Sales per employee in the market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company dominating the cystic fibrosis treatment market and developing new therapies, including CRISPR. This chart shows the average revenue per employee in this segment, demonstrating the exceptional productivity of their R&D in this narrow but highly profitable niche compared to other pharmaceutical companies.
Sales per employee for the market as a whole
Vertex Pharmaceuticals is a biotech company known for its monopoly on drugs for the treatment of cystic fibrosis. It's a rare disease, but the medications are extremely expensive. This chart is a prime example of how focusing on a single niche and breakthrough R&D allows the company to generate enormous revenue, achieving absolute dominance in its market.
Short shares by company, segment and market as a whole
Shares shorted by company Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals is a biotech company that dominates the cystic fibrosis (CF) treatment market. The bearish sentiment seen in this chart stems from concerns that the company is overly reliant on a single segment (CF). Investors doubt that R&D in other areas (such as pain management or diabetes) will yield comparable success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Vertex-Pharmaceuticals-VRTX&v=1772613409709 "Short Shares Chart for the Company Vertex Pharmaceuticals (VRTX)")
Shares shorted by market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company that dominates the treatment of cystic fibrosis. It is now actively pursuing new breakthroughs in other areas, such as pain management. This chart reflects the overall sentiment in the sector. It reflects investor concerns about biotech companies' reliance on a single blockbuster or the risks associated with clinical trials.
Shares shorted by the overall market
Vertex is a biotech company with a virtual monopoly on cystic fibrosis treatment. Their drugs are life-saving, making demand completely inelastic. This chart shows the overall market pessimism. For Vertex, it's less important than for others, but when fear runs high, investors flee even biotech for cash.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Vertex Pharmaceuticals (VRTX)
Vertex is a biotech leader with a monopoly on the cystic fibrosis drug market. This chart measures momentum. "Overbought" (above 70) often means investors are excited not only about the current "money machine" but also about R&D successes in new areas (e.g., pain treatment). "Oversold" (below 30) may signal a rare R&D failure or fear that competitors will eventually threaten the monopoly.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Vertex-Pharmaceuticals-VRTX&v=1772613409780 "RSI 14 indicator chart for the company's stock Vertex Pharmaceuticals (VRTX)")
RSI 14 Market Segment - Specialized pharma
Vertex (VRTX) is a biotech company with a monopoly on cystic fibrosis (CF) treatments. Their challenge is diversification before patents expire. This chart shows the overall sentiment in the biotech sector. It helps us understand: is Vertex overbought due to its unique strength in CF, or is the entire specialty pharma sector riding a wave of optimism?
RSI 14 for the overall market
Vertex Pharmaceuticals is a biotech company that has transformed the lives of people with cystic fibrosis. They are an example of a company focused on scientific breakthroughs. This market sentiment chart has little impact on their research. Demand for their unique drugs is inelastic. Market panic may temporarily reduce the stock price, but not the value of their research portfolio.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VRTX (Vertex Pharmaceuticals)
This chart shows analyst expectations for Vertex. It's one of the few biotech companies with a dominant franchise (cystic fibrosis). Target prices depend on whether Vertex can use its cash to create the "next" blockbuster—in the treatment of type 1 diabetes or pain. The consensus is faith in their R&D machine.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VRTX-Vertex-Pharmaceuticals&v=1772613409865 "A chart showing analyst consensus forecasts for the expected stock price. VRTX (Vertex Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price VRTX (Vertex Pharmaceuticals)
Vertex is a leading biotech company with a monopoly on cystic fibrosis treatments. They use the proceeds from this to invest in breakthrough technologies (CRISPR, pain treatment). This chart shows how much analysts believe in their R&D pipeline beyond cystic fibrosis. It reflects the difference between the consensus estimate and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VRTX-Vertex-Pharmaceuticals&v=1772613409872 "A chart showing the difference between the consensus forecast and the actual stock price. VRTX (Vertex Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Vertex Pharmaceuticals is a biotech company known for its dominant cystic fibrosis (CF) franchise. The company is seeking new growth opportunities. This chart shows analysts' overall expectations for the specialty pharmaceutical sector. It reflects whether experts believe the company's R&D pipeline will be successful beyond CF.
Analysts' consensus forecast for the overall market share price
Vertex Pharmaceuticals is a biotech company known for its breakthrough treatment for cystic fibrosis. It has a history of innovation and niche dominance. This overall market sentiment chart is important for Vertex. Biotech is a sector that requires significant R&D expenditures. Market optimism facilitates access to capital to fund breakthrough research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotech company with an absolute monopoly on cystic fibrosis (CF) treatments. Their drugs have transformed patients' lives and are hugely profitable. This chart reflects this unique position. It measures the sustainability of their CF franchise and the market's confidence that they can leverage this profit to create the next blockbuster in other areas (such as pain treatment).
AKIMA Market Segment Index - Specialized pharma
Vertex Pharmaceuticals is a biotech company with a monopoly in cystic fibrosis treatment and is actively developing drugs for other rare diseases. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark provides insight into how Vertex's dominance in its niche and its scientific R&D distinguish it from the average pharmaceutical company.
The AKIM Index for the overall market
Vertex Pharmaceuticals is a biotech company with a monopoly on cystic fibrosis treatments. The company uses revenue from this franchise to fund breakthrough R&D in other areas (such as gene therapy). This chart, which reflects the market average, provides context. It helps us assess how this focused scientific story, driven by the laws of biotech, compares to the broader macroeconomic trends that influence investor sentiment.
